Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology. Associations between viral infections and the onset of SLE have been suggested, and recent studies have provided evidence that type I interferons (IFNa/b) might play a role in the SLE disease process. Viruses and interferons have also been implicated in mouse models of SLE. We generated a model of accelerated proteinuria, in which lupus-prone mice were injected repeatedly with polyinosinic:polycytidylic acid (polyI:C), mimicking exposure to virus-derived double stranded RNA (dsRNA), leading to the production of IFNa/b. PolyI:Ctreated (B6.Nba2 Â NZW)F1 and (B6 Â NZW)F1 hybrid mice developed significantly increased levels of anti-dsDNA autoantibodies, characteristic of lupus. Most significantly, polyI:C-treated (B6.Nba2 Â NZW)F1 mice, but not (B6 Â NZW)F1 or parental strains, developed lupus-like nephritis in an accelerated fashion, which was dependent on IFNa/b and associated with elevated deposition of total IgG, IgG2a and complement factor C3 in the glomerular capillary walls. These data suggest that reagents, which increase the levels of endogenous IFNa/b (directly or indirectly), can accelerate the course of lupus-like nephritis, the development of which is dependent on the presence of both NZW-and Nba2-encoded genes.
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease that usually develops in women between the ages of 15 and 40 years. The disease affects a variety of organs including the kidney, brain, skin and joints. Elevated levels of antinuclear autoantibodies (ANA) are considered to be a hallmark of disease. 1 Several mouse models of SLE exist. In many of these, mice develop elevated levels of ANA and kidney failure, mimicking manifestations seen in patients with lupus nephritis. 2, 3 Still, some mouse models of SLE show deposition of immunoglobulin G (IgG) immune complexes (IC) in the kidney glomeruli without this leading to kidney disease, suggesting that elevated ANA production and IC deposition in themselves are insufficient for full disease development. 4, 5 Studies have suggested that susceptibility to renal failure is genetically defined.
For example, it has been shown that New Zealand White (NZW) mice are more susceptible than other mouse strains to kidney damage inflicted by autoantibodies. 6 B6.Nba2 mice, in which the Nba2 (New Zealand Black autoimmunity 2) locus on distal chromosome 1 is derived from the New Zealand Black (NZB) strain, 7 develop elevated levels of circulating IgG ANA and IC deposition in the kidney glomeruli by the time they are 2-3 months old. 4, 7 However, these mice fail to develop proteinuria and show no evidence of accelerated mortality when compared to normal B6 mice. In contrast, 490% of (B6.Nba2 Â NZW)F1 female mice develop signs of lupus-like nephritis starting around 6 months of age, 7 supporting the idea that NZW animals encode gene(s) that increase their susceptibility to kidney damage. 5 Viral infections elicit a strong antiviral response, characterized by the induction of type I interferon (IFNa/b), and several studies have suggested that IFNa/b play a role in the development and activity of lupus in both mouse models and patients. [8] [9] [10] For example, SLE patients with active disease have been found to express increased amounts of IFNa/b and a gene expression profile indicative of active IFNa/b signaling. 11, 12 Likewise, a recent study has described a strong correlation between the expression level of IFNa/ b-inducible genes and renal disease. 13 In support of a role for IFNa/b during the induction of lupus, lupus-prone mice that cannot signal through the IFNa/b receptor fail to develop lupus-like disease, 8, 10 and treatment of (NZB Â NZW)F1 lupus susceptible mice with IFNa accelerates disease development and death.
14 Doublestranded RNA (dsRNA) is expressed by some types of viruses. PolyI:C mimics dsRNA and induces IFNa/b and proinflammatory cytokine production after binding to and signaling through the toll-like receptor-(TLR-) 3. [15] [16] [17] or the dsRNA-dependent protein kinase R. 18 In addition, polyI:C upregulates the expression of major histocompatibility complex (MHC) and costimulatory molecule genes, making the compound a powerful activator of not just the innate but also the adaptive immune system. 19 We have tested whether treatment with polyI:C could accelerate or induce renal disease in lupussusceptible mice and, if so, whether the effect of polyI:C was mediated by IFNa/b. We found that mice, which spontaneously develop kidney disease (i.e. (B6.Nba2 Â NZW)F1 mice), but not their parental strains, which are resistant to kidney disease, responded to polyI:C by accelerated disease development. The disease appeared to involve increased levels of serum antidsDNA antibodies and circulating gp70 IC. Elevated levels of ANA and gp70 IC were not sufficient for the development of kidney disease, as the polyI:C-treated (B6 Â NZW)F1 mice, which also had increased levels of ANA and gp70 IC, remained healthy. Treatment of IFNa/ b-receptor-deficient mice with polyI:C did not result in elevated ANA and gp70 IC levels, suggesting that this is an IFNa/b-dependent process. Given the kinetics and incidence of disease, we suggest that polyI:C treatment accelerates spontaneous development of lupus-like disease in genetically predisposed animals rather than induce additional disease, making the model a useful tool in future analyses of the effect of IFNa/b on mouse lupus.
Results
(B6. Nba2 Â NZW)F1 females respond to polyI:C injections with accelerated proteinuria and death B6.Nba2, (B6.Nba2 Â NZW)F1, B6, (B6 Â NZW)F1 and NZW mice were injected with polyI:C or phosphatebuffered saline (PBS) twice a week for 6-12 weeks, starting when the mice were 5-6 weeks old. (B6.Nba2 Â NZW)F1 mice responded to polyI:C by developing accelerated proteinuria in comparison with their untreated controls ( Table 1 ). All the mice that died or were euthanized for signs of illness had severe proteinuria before study completion. B6.Nba2, B6, NZW and (B6 Â NZW)F1 mice all lived for the duration of the study (30 weeks of age) and did not develop any signs of proteinuria. To find out whether the proteinuric (B6.Nba2 Â NZW)F1 mice treated with polyI:C had developed kidney failure at any time during the study period, we tested six of these mice for serum urea nitrogen (SUN) levels as a measure of kidney function. Five of them with a 3 þ score of proteinuria showed elevated levels of SUN (419 mg/dl, the level observed in normal B6 mice), and, of these, two had greatly elevated levels (4100 mg/dl). The levels in mice without proteinuria never exceeded 15 mg/dl (data not shown). It should be noted that elevated SUN levels are only achieved when the mice are terminally sick, whereas elevated levels of proteinuria can be present for several weeks before the mice succumb to the disease. Therefore, we believe that the remaining mouse would eventually have developed elevated SUN levels, had it not been euthanized owing to continuous severe proteinuria.
PolyI:C treatment leads to a transient induction of IFNa/b
It is well known that repeated exposure to ligands can lead to downregulation and/or desensitization of target TLRs, and thus unresponsiveness to further challenge with ligand. 20, 21 To find out whether or not repeated 
Abbreviations: B6, C57BL/6; Nba2, New Zealand Black Autoimmunity 2; NZW, New Zealand White; PBS, phosphate-buffered saline. Included in this table are cohorts of mice followed until at least 30 weeks of age. *Po0.05; PBS-vs polyI:C-treated mice. pI:C ¼ polyI:C.
PolyI:C induces accelerated disease in lupus mice TN Jørgensen et al injections of polyI:C were similarly affecting TLR3 function, we studied the effects of repeated injection of polyI:C on IFNa/b production. We measured serum levels of IFNa/b 1.5, 3 and 6 h after polyI:C injection. Initially, all mice responded to polyI:C by a rapid and transient induction of IFNa/b (Figure 1a) . After seven injections, re-administration of polyI:C resulted in little IFNa/b production, and after 13 injections no induction of IFNa/b could be detected (Figure 1b ). This loss of response was not due to a general block of IFNa/b production, as these mice produced IFNa/b in response to a TLR7 agonist (S27609) (Figure 1c ).
(B6.Nba2 Â NZW)F1 mice treated with polyI:C show significantly increased levels of serum anti-dsDNA autoantibodies Untreated B6.Nba2 and (B6.Nba2 Â NZW)F1 mice develop comparable levels of ANA; however, only the F1 cross has high levels of circulating gp70 IC. 7 As the lupus-like disease that spontaneously develops in (B6.Nba2 Â NZW)F1 mice correlates with elevated levels of ANA and gp70 IC, we analyzed the presence of these antibodies in serum samples of polyI:C-or PBS-treated mice. We found that polyI:C treatment increased the levels of serum anti-dsDNA autoantibodies in 18-weekold (B6.Nba2 Â NZW)F1 mice ( Figure 2 , lower panel), with 12 of 16 mice expressing levels above background (stippled line). Of the six mice with anti-dsDNA autoantibody levels above the mean, three of them had severe proteinuria at the time of sampling (gray symbols), whereas the other three appeared healthy (white symbols). In addition, polyI:C-treated (B6.Nba2 Â NZW)F1 mice expressed significantly elevated levels of anti-ssDNA autoantibodies (Po0.05, data not shown), whereas no significant differences could be detected in the levels of autoantibodies against chromatin or total histones in polyI:C-or PBS-treated (B6.Nba2 Â NZW)F1 mice ( Figure 2 , top panels). Actually, it appeared that polyI:C treatment resulted in slightly reduced levels of autoantibodies with these specificities, although the difference was not statistically significant (P ¼ 0.06 (anti-chromatin IgG) and P ¼ 0.38 (anti-histones IgG)). As the kinetics of autoantibody production could have been significantly altered by polyI:C treatment, we also tested serum from younger mice (i.e. at 10 and 14 weeks of age) for the presence of anti-chromatin and antihistones autoantibodies. We found no differences between polyI:C-or PBS-treated mice (data not shown). In contrast, polyI:C treatment of (B6 Â NZW)F1 mice induced significantly increased levels of all autoantibodies measured, including anti-ssDNA IgG, and resulted in levels comparable to those seen in (B6.Nba2 Â NZW)F1 mice ( Figure 2 and data not shown). This, however, was not enough to induce renal disease (see Table 1 ). NZW mice treated with polyI:C had significantly elevated levels of serum anti-chromatin, antihistones IgG as compared to PBS-treated mice (Figure 2 , top panels), although the levels did not exceed background levels (i.e. untreated age-and sex-matched B6 mice). PolyI:C treatment of B6 mice did not result in increased serum ANA levels (data not shown).
We next tested polyI:C-or PBS-treated mice for serum levels of gp70 IC. Levels of serum gp70 IC increased in (B6.Nba2 Â NZW)F1, NZW and (B6 Â NZW)F1 mice (Figure 3a ), although the difference reached statistical significance only for (B6 Â NZW)F1 mice (Po0.01). The levels of gp70 IC remained unchanged in B6 mice (P ¼ 0.432, data not shown). In contrast, levels of total serum gp70 were comparable between polyI:C and PBS treated groups of each strain (Figure 3b ).
Accelerated kidney disease in polyI:C-treated (B6.Nba2 Â NZW)F1 mice Changes in kidney morphology that occur in the course of lupus nephritis in humans and mice have been well described. 1 Thickening of the glomerular basement membrane, mesangial hypercellularity, endocapillary proliferation and the formation of crescents are just Two mice of each strain (B6.Nba2 Â NZW)F1, B6.Nba2, and (B6 Â NZW)F1 mice were injected i.p. with 100 mg polyI:C in PBS, and the levels of serum IFNa/b were determined at various time points (a). All serum samples were tested in duplicate. Repeated exposure to polyI:C leads to unresponsiveness as measured by IFNa/b induction after injection (b). Two (B6 Â NZW)F1 mice were injected i.p. with 100 mg polyI:C in PBS two times per week. Mice were bled after 1, 7, and 13 injections and the serum levels of IFNa/ b were determined. Similar results were obtained after injection of polyI:C into NZW or B6 mice (data not shown). Mice that failed to produce IFNa/b after repeated exposure to polyI:C (13 injections) produce IFNa/b in response to a TLR7 agonist (S27609) (c). Two (B6 Â NZW)F1 mice were injected 13 times with polyI:C followed by one injection of 100 mg S27609. Serum levels of IFNa/b were determined as described above.
PolyI:C induces accelerated disease in lupus mice TN Jørgensen et al some of the morphologic features associated with antibody-mediated glomerulonephritis in lupus. To find out if such changes were induced in our disease model, we analyzed kidneys from 18-week-old polyI:C-or PBStreated (B6.Nba2 Â NZW)F1 mice (Figure 4a ), as well as polyI:C-or PBS-treated control mice (i.e. (B6 Â NZW)F1, NZW or B6, data not shown). Kidney appearance in PBSor polyI:C-treated (B6.Nba2 Â NZW)F1 mice was blindly scored on a scale from 0 to 3 ( Figure 4b ). We tested four polyI:C-treated (B6.Nba2 Â NZW)F1 mice, of which two had severe proteinuria. These two mice, as well as one mouse without signs of proteinuria, showed diffuse mesangial hypercellularity. In contrast, only one of the PBS-treated (B6.Nba2 Â NZW)F1 mice showed signs of early glomerular proliferation, whereas the remaining three samples, as well as all samples from control (B6 Â NZW)F1, NZW and B6 mice (polyI:C or PBS treated), showed no signs of kidney disease ( Figure 4b and data not shown). Interestingly, the two mice with severe proteinuria and highly elevated serum urea nitrogen levels also had tubulointerstitial lesions (data not shown), which is a known poor prognostic indicator in human glomerulonephritis. 22 Increased levels of IgG are deposited in kidney glomeruli of polyI:C-treated mice To find out if polyI:C-treated mice had antibodymediated damage of kidney glomeruli, we tested polyI:C-and PBS-treated mice for deposition of IC in their kidney glomeruli. Kidneys were harvested from the mice when they were 18 weeks old, at the end of treatment, and stained for the presence of IgG (Figure 5a ). IgG deposition was detected along the glomerular capillary walls and in mesangial areas of polyI:C-treated (B6.Nba2 Â NZW)F1 mice with severe proteinuria (3 þ prot.). PolyI:C-and PBS-treated (B6.Nba2 Â NZW)F1 mice, without proteinuria (no prot.), had IgG deposits in the mesangial areas only, although more IgG could be detected in the polyI:C-treated mice. Mice were bled when 18 weeks old and serum levels of anti-chromatin, anti-histones, and anti-dsDNA were detected by ELISA as described in Materials and methods. Each symbol represents one mouse. Gray symbols: (B6.Nba2 Â NZW)F1 mice with severe proteinuria. No statistical difference in levels of anti-chromatin and anti-histones IgG autoantibodies was observed between polyI:C-and PBS-treated (B6.Nba2 Â NZW)F1 mice; however, polyI:C-treated mice had significantly more anti-dsDNA autoantibody levels (Po0.05). (B6 Â NZW)F1 mice responded to polyI:C treatment by producing more anti-chromatin IgG (Po0.01), more anti-histones IgG (Po0.05), and more antidsDNA (Po0.05). NZW mice responded to polyI:C treatment by increased serum levels of anti-chromatin IgG (Po0.05) and anti-histones IgG (Po0.05), although the levels did not exceed background levels (age-matched untreated B6 females72 s.d., horizontal stippled lines).
Also, NZW and (B6 Â NZW)F1 mice treated with polyI:C had increased IgG deposition in their kidneys as compared to PBS-treated mice, where the levels were almost undetectable. These deposits were limited to mesangial areas too. No significant IgG deposits were observed in B6 mice; PBS or polyI:C treated (data not shown).
In addition to the qualitative differences seen in the staining pattern between groups of mice, we performed morphometric analyses determining the percentage of the glomerular area, which stained positively for IgG, as a quantitative measure of deposition. We found that polyI:C treatment resulted in a significant increase in the amount of IgG deposited in the kidneys of (B6.Nba2 Â NZW)F1 mice (Po0.05) (Figure 5b ). In addition, we observed substantial, but not significant, increases in the amount of IgG deposited in polyI:Ctreated (B6 Â NZW)F1 and NZW mice as compared to PBS-treated controls (data not shown).
Treatment with polyI:C increases the ratio of IgG2a to IgG1 resulting in IgG2a deposition and complement fixation in the kidneys of (B6.Nba2 Â NZW)F1 mice The IgG isotypes associated with mouse lupus-like disease are IgG2a, IgG2b and IgG3. 23 It has previously been shown that polyI:C-induced IFNa/b can increase the levels of IgG2a and the ratio of IgG2a to IgG1. 24, 25 We tested whether polyI:C affected the total levels of serum IgG1 and IgG2a in 18-week-old (B6.Nba2 Â NZW)F1, (B6 Â NZW)F1 and NZW mice. B6 mice do not express IgG2a 26 and were omitted from this analysis. We found that all polyI:C-treated mice expressed more serum IgG2a and less serum IgG1 than their PBS-treated equivalents. PolyI:C induced comparable levels of serum IgG2a in all strains (0.21 mg/ml70.07, 0.18 mg/ml70.02 and 0.16 mg/ml 70.01 for (B6.Nba2 Â NZW)F1, (B6 Â NZW)F1 and NZW, respectively); however, PBS-treated (B6.Nba2 Â NZW)F1 had significantly higher levels of serum IgG2a (0.20 mg/ml70.05) than PBS-treated (B6 Â NZW)F1 and NZW mice (0.14 mg/ml70.01 and 0.13 mg/ml70.02, respectively) (Po0.005). Serum levels of IgG1 were significantly reduced in polyI:Cvs PBS-treated mice of all strains (0.93 mg/ml70.45 vs Figure 3 PolyI:C treatment results in increased levels of serum gp70 IC in (B6.Nba2 Â NZW)F1, (B6 Â NZW)F1, and NZW mice, but does not alter the levels of total serum gp70. Six-week-old (B6.Nba2 Â NZW)F1, (B6 Â NZW)F1, and NZW mice were injected with 100 mg polyI:C (n ¼ 16, 9, 3, respectively) or PBS (n ¼ 9, 9, 4, respectively) as described. Mice were bled when 18 weeks old and serum levels of gp70 IC (a) and total serum gp70 (b) were determined. Levels of total serum gp70 remained unchanged between polyI:C-and PBS-treated mice of each strain, whereas the levels of gp70 IC increased in all groups, although without reaching statistical significance (P ¼ 0.157 for polyI:C vs PBStreated (B6.Nba2 Â NZW)F1, P ¼ 0.008 for polyI:C vs PBS treated (B6 Â NZW)F1, P ¼ 0.057 for polyI:C vs PBS-treated NZW). Only in (B6.Nba2 Â NZW)F1 mice did the levels exceed background levels (age-matched untreated B6 females þ 2 s.d., horizontal stippled lines). Gray symbols: (B6.Nba2 Â NZW)F1 mice with severe proteinuria. pI:C ¼ polyI:C.
PolyI:C induces accelerated disease in lupus mice TN Jørgensen et al (B6.Nba2 Â NZW)F1 mice (polyI:C or PBS treated) than in (B6 Â NZW)F1 and NZW mice (Po0.0005), suggesting a correlation between the ratio of serum IgG2a to serum IgG1 and lupus-like disease development in our model. This was further emphasized by the fact that the highest ratios of IgG2a to IgG1 was found in (B6.Nba2 Â NZW)F1 mice with severe proteinuria (gray symbols, Figure 6a ). As described, the serum levels of IgG2a did not increase significantly in polyI:C-vs PBS-treated (B6.Nba2 Â NZW)F1 mice. This could be either owing to the relatively high levels seen in PBS-treated mice or due to increased deposition, and hence removal from the serum, of IgG2a containing IC in the kidney glomeruli of polyI:C-treated mice. We analyzed kidneys from polyI:Cor PBS-treated (B6.Nba2 Â NZW)F1, (B6 Â NZW)F1 and NZW mice for the presence of IgG2a. Although polyI:Ctreated mice of all three strains stained positive for IgG2a within the mesangium, only (B6.Nba2 Â NZW)F1 with severe proteinuria showed significant depositions along the glomerular capillary walls (Figure 6b) . No significant depositions could be detected in PBS-treated (B6 Â NZW)F1 and NZW mice.
Complement fixation to the glomerular walls is thought to play a major role in the pathogenesis of lupus in mice and humans. We analyzed kidneys from polyI:Cor PBS-treated (B6.Nba2 Â NZW)F1, (B6 Â NZW)F1 and NZW mice for the presence of complement factor C3 as an indicator of complement activation (Figure 6b) . PolyI:C-treated (B6.Nba2 Â NZW)F1 mice, with or without proteinuria, as well as polyI:C-treated (B6 Â NZW)F1 mice showed extensive glomerular deposition of C3. Depositions covered both mesangial areas and the glomerular walls. In contrast, NZW and all PBS-treated mice had C3 deposition predominantly along the tubules and Bowman's capsule, although some C3 could also be detected within the mesangial areas of the glomeruli in (B6.Nba2 Â NZW)F1 and NZW mice. Low-affinity binding of anti-C3 antibodies to tubules and Bowman's capsules could also be seen in B6 mice and had previously been referred to as irrelevant for mouse lupus-like disease. 27 IFNa/b signaling is required for the induction of autoantibodies in polyI:C-treated mice We believe that the effects seen in response to polyI:C are mediated mainly by the induction and function of IFNa/ b. However, it has been shown that polyI:C might induce the production of proinflammatory cytokines and interferon-gamma, 28 which could potentially be the cause of the accelerated kidney disease in our model. In order to investigate whether IFNa/b signaling was required for the induction of serum autoantibodies, gp70 IC and the increased IgG2a:IgG1 ratio in response to polyI:C, we backcrossed IFNa/b receptor (IFNAR)-deficient mice onto B6.Nba2 and NZW. Analyses of polyI:
and IFNAR À/À (B6.Nba2 Â NZW)F1 mice showed that although polyI:C treatment resulted in the induction of ANA in IFNARexpressing mice (Po0.001 for all three autoantibody specificities), no significant difference could be seen when comparing treated or untreated IFNAR À/À mice (Figure 7a , P ¼ 0.58, P ¼ 0.06, P ¼ 0.79 for anti-chromatin IgG, anti-histones IgG and anti-dsDNA IgG, respectively). There was no difference in the levels of autoantibodies produced by untreated IFNAR-expressing ( þ / þ or þ /À) and IFNAR À/À mice, although there was a trend towards higher levels in IFNARexpressing mice, suggesting a role for endogenous IFNa/ b signaling. Levels of serum gp70 IC in 18-week-old mice were leaning in the same direction (Figure 7b ), however these data did not reach statistical significance and data from older mice (32 weeks of age) showed no difference between the groups (data not shown). Interestingly, when analyzing serum samples from 18-week-old mice for the distribution of total IgG2a and IgG1, polyI:Ctreated IFNAR À/À mice showed the same ratio of IgG2a to IgG1 as did IFNAR (Figure 7c) . Thus, the shift towards IgG2a production might be dependent on the effect of other cytokines or interferons not using the IFNAR-1 receptor (i.e. IFNg or IFNl). Among polyI:
(B6.Nba2 Â NZW)F1 mice, only one out of eight (12.5%) developed severe proteinuria (at 22 weeks of age), which is less than in the polyI:C-treated (B6.Nba2 Â NZW)F1 mice, although not statistically different (P ¼ 0.0571). Of the untreated mice, two out of 13 (15%) had developed severe proteinuria at 7 months of age, which was comparable to the incidence seen in 7-month-old, (B6.Nba2 Â NZW)F1 mice showed that polyI:C-treated, IFNAR-deficient mice had less IgG deposition and no fixation of complement (Figure 7d ). Taken together, these data strongly suggest that the induction of autoantibody production, IgG deposition in and C3 fixation to the kidney glomeruli, and the accelerated development of lupus-like kidney disease in polyI:C-treated (B6.Nba2 Â NZW)F1 mice were the results of increased IFNa/b signaling.
Discussion
One of the main effects of polyI:C administration is the induction of IFNa/b production, and recent studies of mouse and human lupus have suggested a correlation between levels of endogenous IFNa/b and disease severity. 8, [11] [12] [13] [14] The IFNa/b-family consists of a number of IFNa's as well as IFNb and IFNo. 29 Although all members of the IFNa/b family bind and signal through the same receptor, they are expressed by different cell populations and may exert different functions in vivo. We treated lupus-prone mice with the development of accelerated fatal kidney disease in (B6.Nba2 Â NZW)F1 mice.
In this model of accelerated lupus-like disease, polyI:C probably caused disease via antibody deposits in the kidneys, as the affected (B6.Nba2 Â NZW)F1 animals developed proteinuria and had increased deposition of IgG, particularly IgG2a, in their kidneys. More specifically, (B6.Nba2 Â NZW)F1 mice with severe proteinuria showed IgG2a deposits and fixation of C3 to the glomerular walls. Such a pattern is indicative of severe glomerular disease and was not observed in (B6 Â NZW)F1 or NZW mice, treated or untreated. The specificity of these damaging antibodies is not, however, clear. It is well known that B6.Nba2 and (B6.Nba2 Â NZW)F1, but not B6 or NZW mice, spontaneously develop significant levels of ANA. 5, 7 Elevated serum anti-chromatin and anti-histones autoantibodies are first detectable in 3-to 5-month-old unmanipulated (B6.Nba2 Â NZW)F1 mice. In contrast, the spontaneous production of anti-dsDNA IgG is only detectable after 5-6 months. Although the differences fail to reach statistical significance, the levels of anti-chromatin and antihistones autoantibodies appear to be slightly reduced in polyI:C-treated mice. A possible explanation for this finding is the idea that the polyI:C treatment has altered the kidneys of (B6.Nba2 Â NZW)F1 mice, making them more susceptible to IgG deposition. Thus, the slightly lower levels of serum anti-chromatin/histones autoantibodies might be owing to increased deposition of such antibodies. Further studies, however, are needed to prove this definitively. It was previously published that the levels of anti-dsDNA autoantibodies were elevated in a model of IFNa/b-induced kidney disease in (NZB Â NZW)F1 mice, 14 and autoantibodies against dsDNA are generally believed to be pathogenic. The presence of anti-dsDNA antibodies in polyI:C-treated (B6 Â NZW)F1 mice, which remain healthy, suggest that these antibodies in themselves are not enough to cause kidney disease. Finally, polyI:C administration tended to increase the levels of another set of autoantibodies against gp70. These autoantibodies have been suggested to play an important role in murine lupus-like nephritis, 30, 31 but probably plays a minor role in this model, as the levels did not increase significantly in polyI:C-vs PBS-treated (B6.Nba2 Â NZW)F1 mice. Thus, some other antibody, directed against a different set of antigens, may be the causative agent.
PolyI:C treatment induces not only IFNa/b production but also the production of proinflammatory cytokines such as interleukin (IL)-6 and IFNg. 28 Thus, polyI:Cmediated accelerated proteinuria could be independent of the induction of IFNa/b, as previously suggested in studies of polyI:C-induced lupus-like disease in MRL-lpr mice. 32 We generated IFNAR-deficient (B6.Nba2 Â NZW)F1 mice and treated them with polyI:C in order to investigate the importance of IFNa/b in our model. We found that serum levels of ANA, IgG deposition and C3 fixation were significantly reduced in polyI:C-treated (B6.Nba2 Â NZW)F1 mice were analyzed, it appeared that polyI:C treatment increased the production of all antinuclear autoantibodies in these mice. This effect could be due to the induction of increased levels of IFNg in IFNAR À/À mice, a phenomenon that has previously been described. 33 In agreement with this idea, we found that polyI:C-treated IFNAR À/À (B6.Nba2 Â NZW)F1 mice expressed an increased ratio of IgG2a to IgG1, a known response to IFNg. Alternatively, this difference might be owing to the diverse genetic background of the two crosses, that is, the lack of NZW-derived suppressor (Sles) genes 34 or the introduction of additional 129-derived susceptibility loci in IFNAR-targeted (B6.Nba2 Â NZW)F1 offspring. 35 Repeated stimulation through TLR-2, -4 and -9 lead to downregulation or desensitization of the receptors. 20, 21 Likewise, whereas initial stimulation with polyI:C leads to the production of large amounts of IFNa/b, repeated exposure results in unresponsiveness and lack of IFNa/b production. In addition, polyI:C treatment leads to a transient increase in the levels of serum IFNa/b, with levels peaking at 1.5 h post injection. Taken together, in our model of accelerated lupus-like disease, polyI:Ctreated mice express transiently elevated levels of serum IFNa/b two times per week for a maximum of 6 weeks. With this in mind, it is impressive that polyI:C-treated mice develop kidney disease much earlier than PBStreated mice. This, however, might also explain why we see less of an impact than previously described in IFNatreated (NZB Â NZW)F1 mice.
14 In that study, mice were injected with either adenoviral particles expressing recombinant mouse IFNa5 or an osmotic pump continuously releasing recombinant IFNaA. These manipulations resulted in continuously elevated levels of serum IFNa and the development of accelerated proteinuria and death in 100% of the treated mice. Several studies have suggested that viral infections might precede the development of lupus in susceptible individuals. [36] [37] [38] [39] Viral infections most often result in a transient rather than continuous boost in IFNa/b production. Our data support the idea that a transient increase in IFNa/b levels might be sufficient to trigger the immune process leading to the development of systemic autoimmunity in genetically susceptible individuals.
Significantly, the effects of polyI:C depended on the genetic background of the mice, as kidney disease as manifested by elevated proteinuria levels was observed in neither of the parental strains (B6.Nba2 and NZW) nor in control (B6 Â NZW)F1 mice, but only in (B6.Nba2 Â NZW)F1 mice. Therefore, the polyI:Cmediated accelerated disease is controlled by a combination of genes derived from both NZW and from the Nba2 interval. As mentioned above, IFNa also induces disease in (NZB Â NZW)F1 mice.
14 In that study, however, the effect of Nba2-encoded genes could not be evaluated, so the data presented here are the first to show the importance of the Nba2-region during lupus-like disease development in response to IFNa.
Several NZW-derived lupus susceptibility loci affecting autoantibody production, T-and B-cell function and end-organ (kidney) susceptibility to inflammatory damage have been identified. 6, 40, 41 The Nba2 interval comprises approximately 40 Mb and codes for about 350 genes on distal chromosome 1 (Ensembl MSGC database) and has been linked to both autoantibody production and kidney disease. 2, 5, 7, 42, 43 Within the region are located numerous genes encoding proteins that might affect the development of lupus-like disease in B6.Nba2 mice and be subjected to IFNa/b-dependent regulation. For example, genes affecting apoptosis, such as Tnfsf6 (Fas ligand) and Apsc (Serum amyloid P), lie in this interval. Both of these genes have been suggested as major players in mouse lupus-like disease. 44, 45 Also encoded is the interferon-inducible p200 family of proteins involved in cell cycle regulation. 46, 47 Of these, p202, encoded by Ifi202, has been associated with mouse lupus-like disease. 7 Other interesting candidates encoded within this region includes Ly108, 48 the inhibitory IgG receptor FcgRIIb, 49, 50 the xenotropic retroviral receptor 1 protein (Xpr1), which confers susceptibility to retroviral infection 51 and podocin, a protein that is involved in kidney function, 52 although any regulation by IFNa/b has not been documented. Further studies are needed to find out which of these candidates is the essential Nba2-derived contributor to the accelerated disease seen in polyI:C-treated (B6.Nba2 Â NZW)F1 mice.
As mentioned, increased expression of interferonregulated genes has been found in SLE patients and mouse models of lupus-like disease. Some of these genes (such as BAFF, MCP-1 and IRF-1) have been assigned a functional role in mouse lupus development. 4, 53, 54 Future studies combining polyI:C treatment with systemic blockade of BAFF, MCP-1, IRF-1 or other IFNa/b induced factors might help define the pathway(s) by which increased endogenous IFNa/b can result in accelerated lupus-like disease.
In summary, the experiments described here show that polyI:C can accelerate kidney disease in lupus-prone mice. The effects of polyI:C is mediated mainly by IFNa/ b, but the outcome of treatment depends upon the genotype of the targeted mice, that is, only mice expressing genes, which render their kidneys and immune systems appropriate targets, develop accelerated kidney disease.
Materials and methods

Mice and treatments
The congenic B6.NZB-Nba2 (B6.Nba2) strain was generated in our laboratory. 7 NZW/LacJ and C57BL/6 (B6) mice were purchased from The Jackson Laboratory, Bar Harbor, ME, USA. IFNa/b-Receptor (IFNAR)-deficient mice 55 were provided by Dr Aguet, ISREC, Switzerland, and backcrossed to B6.Nba2 (six generations) and NZW (three generations). All mice studied were females. The mice were kept at the University of Colorado Health Sciences Center Animal Facility following US animal welfare guidelines, and as approved by the Animal and Care Use Committee of the University of Colorado Health Sciences Center (Denver, CO, USA). Six-week-old mice were treated i.p. with 100 mg polyI:C (SigmaAldrich) in sterile PBS or control sterile PBS two times per week for up to 12 weeks. Mice were monitored for the development of proteinuria by dipsticks (Chemstrip 2 GP, Roche Diagnostics) and bled by tail vein incision before treatment with polyI:C (age 6 weeks), and at 18 and 32 weeks of age. Mice with proteinuria readings of X2 þ (100 mg/dl) on two consecutive readings (less than 2 weeks apart) were designated as positive for severe proteinuria and renal disease. In studies addressing the capability of polyI:C-treated mice to produce IFNa/b in response to a different stimulus, mice were injected i.p. with 100 mg TLR7 agonist (S27609, a kind gift from Dr R Kedl, University of Colorado Health Sciences Center and National Jewish Medical and Research Center) in sterile PBS. Serum urea nitrogen was determined for each mouse using a Beckman Autoanalyzer (Beckman, Fullerton, CA, USA) and presented as mg/dl. Control B6 mice had serum urea nitrogen levels of 1971 mg/dl.
IFNa/b bioassay
We used L929 fibroblasts stably transfected with an ISRE (5 Â )-HSV-TK promoter-luciferase construct (Clontech, Mountain View, CA, USA) to develop a bioassay, which could detect even very low levels of IFNa/b. Briefly, L929/ISRE-luc cells were plated as 2 Â 10 4 cells/well in a 96-well plate and allowed to adhere overnight. Supernatants were removed and replaced with fresh medium containing serum (1:50 dilution) from polyI:C-or PBStreated mice or control recombinant IFNa (BioSource International, Camarillo, CA, USA) for 7-8 h. Luciferase activity was measured using a luciferase assay system (Promega, Madison, WI, USA) and an Lmax luminometer (Molecular Devices, Sunnyvale, CA, USA). Levels of IFNa/b were calculated based on a standard curve obtained by recombinant IFNa titration (2-125 U/ml).
Detection of serum IgG1 and IgG2a levels by enzyme-linked immunosorbent assay (ELISA)
Immulon II microtiter plates (Thermo Labsystems, Milford, MA, USA) were coated with 2.5 mg/ml goat anti-mouse Ig (Kirkegaard & Perry Laboratories, Gaithersburg, MD, USA) in PBS and blocked with PBSgelatin. Sera were diluted 1:50 000 and 1:100 000 in assay buffer (5 mg/ml bovine g-globulin, 5% gelatin, 0.05% Tween-20 in PBS), added to the plates and incubated for 90 min at room temperature. After washing in PBS, secondary horseradish peroxidase (HRP)-conjugated goat anti-mouse antibodies (goat anti-mouse IgG2a or goat anti-mouse IgG1, both from Southern Biotechnology Associates, Birmingham, AL, USA) were added for 1 h, and amounts of antibodies were visualized by ABTS substrate (Sigma, St Louis, MO, USA) on a Vmax kinetic microplate reader (Molecular Devices) and analyzed using Softmax s software. A standard curve was generated using serial dilutions of mouse IgG1 or IgG2a (biotinylated, Caltagt Laboratories, Invitrogen, Carlsbad, CA, USA).
Detection of serum ANA levels by ELISA Levels of autoantibodies to chromatin, histones and dsDNA were detected in serum samples from treated mice as previously described. 42, 43 Briefly, 96-well plates (Immulon II HB microtiter plates, Thermo Labsystems) were coated overnight with isolated chromatin, total purified calf thymus histones or streptavidin followed by biotinylated pGEM plasmid DNA (Stratagene, La Jolla, CA, USA), washed and blocked with PBS-gelatin. Sera were diluted 1:300 in assay buffer (see above) and applied. Concentrations of serum IgG antibodies were detected using a peroxidase-conjugated goat anti-mouse IgG antibody (Kirkegaard and Perry Laboratories) and ABTS substrate as described above. Standard curves were obtained using serial dilutions of monoclonal antibodies specific to DNA (clone 1D12) or histone 2A (clone 2B1). All concentrations are given in units/ml. Background levels represent the mean þ 2SD of untreated age-matched female B6 mice.
Detection of serum gp70 and serum gp70 IC Concentrations of total (free and antibody bound) gp70 in sera were determined by ELISA as described previously. 56 Serum levels of antibody-bound gp70 (gp70 IC) were quantified by the same ELISA combined with the treatment of sera with 10% polyethylene glycol (average molecular weight 6000), which precipitates only antibody-bound gp70, but not free gp70, as described. 56 Results are expressed as mg/ml of gp70 by referring to a standard curve obtained from a serum pool of NZB mice with known amounts of gp70. The level of detection was 0.05 mg/ml for gp70 IC. Background levels represent the mean þ 2SD of untreated age-matched female B6 mice.
Kidney histology
Kidneys were obtained from mice treated with polyI:C or PBS for 12 weeks. Half a kidney was fixed in 10% formalin and embedded in paraffin for immunohistochemical analyses. Three mm sections from eight (B6.Nba2 Â NZW)F1 mice (4 Â polyI:C and 4 Â PBS treated) and four of each (B6 Â NZW)F1, NZW and C57BL/6 (2 Â polyI:C and 2 Â PBS or untreated) mice were prepared and stained with hematoxylin/eosin. Three independent sections (45 mm apart) were stained per sample and 410 glomeruli/sample were examined and semiquantitatively scored in a blinded fashion. Each glomerulus was given a score from 0 to 3: 0, normal morphology; 1, some mesangial cell proliferation; 2, mesangial proliferation and some endocapillary changes; 3, mesangial proliferation, endocapillary proliferative changes and tubular interstitial damage.
Another half kidney was quick-frozen in Tissue-Tek (OCTt) for immunoflourescence staining. Sections (5 mm) were cut, blocked with rabbit non-immune serum and stained for the presence of mouse IgG, IgG2a or complement factor C3 using an FITC-conjugated rabbit anti-mouse IgG antibody (MP Biomedicals, Solon, OH, USA), a TexasRed conjugated goat anti-mouse IgG2a antibody (SouthernBiotech) or an FITC-conjugated goat anti-mouse C3 antibody (MP Biomedicals), respectively. We analyzed at least two independent kidneys per strain per treatment and 2-3 independent sections (480 mm apart) per sample. Microscopy and morphometric analyses were carried out blinded on 6-9 glomeruli per kidney using an Olympus BX51 microscope, attached to a Pixera CL600 color CCD camera and a computer running the ImagePro software v4.5 program (Media Cybernetics). All pictures were taken with a fixed exposure time, making levels of fluorescence directly comparable between samples.
Statistical analyses
The statistical significance between polyI:C-and PBStreated mice was determined using the nonparametric Mann-Whitney U-test. Differences in the incidence of proteinuria and mortality were determined using curve comparison analyses.
Abbreviations ANA, antinuclear autoantibody; B6, C57BL/6; ds, double stranded; EBV, Epstein-Barr virus; IC, immune complex; IFNa/b, type I interferons; Ig, immunoglobulin; Nba2, New Zealand Black Autoimmunity 2; NZB, New Zealand Black; NZW, New Zealand White; pI:C, polyI:C; SLE, systemic lupus erythematosus.
